ISSN No:-2456-2165 https://doi.org/10.38124/ijisrt/25jul517

Emerging Diagnostic and Therapeutic Strategies in Renal Cell Carcinoma

Thilagavathi M[1*]; Natarajan Kumaresan[2];
Chandru Thirunavukkarasu[3]; Rubina Singh[4]

[1]Faculty of Allied Health Science, Urology Technology, Sri Ramachandra Institute of Higher Education and Research, Porur, Chennai, Tamil Nadu, India

[2]Chandru Thirunavukkarasu, and Ruina Singh, Department of Urology, Sri Ramachandra Institute of Higher Education and Research, Porur, Chennai, Tamil Nadu, India

[3,4] Department of Urology, Sri Ramachandra Institute of Higher Education and Research, Porur, Chennai-116, Tamil Nadu, India.

Corresponding Author: Thilagavathi M*

Publication Date: 2025/07/14

Abstract:

- ***Background:***
  Renal cell carcinoma (RCC) is the most common kidney cancer nearly 3% of all malignancies. Prominent advances in molecular biology and immunotherapy have revolutionized the understanding and treatment of RCC, resulting in favorable outcomes of patients.

- ***Objectives:***
  This review focus on molecular mechanisms of RCC, diagnostic strategy advances, and emerging therapeutic strategies. Innovative therapies and areas of future research are highlighted with a view to augmenting personalized medicine.

- ***Materials and Methods:***
  A systematic reviews was undertaken on medical article publications over the past 6 years. Mainly focused on renal cell carcinoma, molecular pathways, immune checkpoint inhibitors, and targeted therapies. Following the selection of articles, findings regarding RCC pathogenesis, diagnostics, and treatment advances were determined.

- ***Result:***
  Recent research has also defined molecular changes, including Von Hippel Lindau (VHL) gene changes and hypoxia-inducible factors, that are responsible for RCC development.

  The advantages of immune checkpoint inhibitors, such as nivolumab and pembrolizumab, as mono therapies or in combination with targeted therapy, have improved positive outcomes for advanced RCC.

- ***Conclusions:***
  In RCC biology and immunotherapy have improved outcomes for kidney cancer. Continuous investigation into biomarkers and molecular targets is important for expanding personalized therapies, improving effect, and sustaining to enhance positive outcomes.

Keywords*: Biomarkers, Hypoxia Inducible Factors, Immune Check Point Inhibitors, Immunotherapy, Renal Cell Carcinoma, Targeted Therapy.*

ISSN No:-2456-2165 https://doi.org/10.38124/ijisrt/25jul517

How to Cite: Thilagavathi M; Natarajan Kumaresan; Chandru Thirunavukkarasu; Rubina Singh (2025) Emerging Diagnostic and Therapeutic Strategies in Renal Cell Carcinoma. *International Journal of Innovative Science and Research Technology*, 10(7), 566-570. https://doi.org/10.38124/ijisrt/25jul517

I. INTRODUCTION

Renal cell carcinoma (RCC) is the most common kidney cancer in adults and approximately 2-3% of adult cancers in the world. Its frequency has been increasing, contributed by enhanced imaging and early detection. RCC's biological heterogeneous is evidence with a number of histopathological subtypes, the most common being clear cell RCC, accounting for approximately 75% of cancer populations. In spite of improvements in surgical interventions and therapies against specific targets, metastatic renal cell carcinoma remains a major clinical challenge, with 5 year survival rates < 15% (1) .

RCC pathogenesis has been well studied and has identified key molecular mechanisms of tumor development. One of the indicative occurrences in clear cell RCC is the lack of the Von Hippel-Lindau (VHL) tumor suppressor gene, which induce stabilization of hypoxia-inducible factors (HIFs). These transcriptional factors produce the up regulation of angiogenic factors like vascular endothelial growth factor (VEGF), allowing the promotion of tumor angiogenesis and development (2) .

This insight has proved invaluable to the creation of targeted therapies, such as VEGF pathway inhibitors sunitinib, pazopanib, and cabozantinib, which have markedly enhanced progression-free survival and overall response rates in advanced disease patients (3).

Although targeted agents have significant changes RCC treatment, resistance is still a noticeable challenge. Tumors tend to escape by developing different angiogenic tacks or mechanisms of immune shift, resulting in progression of the disease. Understanding these deficiencies, recent literature has turned its focusing to immunotherapy, and more specifically immune checkpoint inhibitors. Programmed cell death -1/Programmed cell death-L1 pathway targeting agents like nivolumab have shows long lasting responses and survival benefits in metastatic advance disease (4). For example, the Check Mate 214 trial demonstrated that the combination of nivolumab with ipilimumab (a CTLA-4 inhibitor) produced better result of overall survival and response rates than sunitinib, confirming the role of immunotherapy as an reliable main method of RCC management (5).

In addition, combining immunotherapy and targeted therapies has shown positive results. The KEYNOTE-426 trial demonstrated how pembrolizumab combined with axitinib benefited improve overall survival and response rates compared to sunitinib mono therapy in treatment advanced RCC patients (6) .

Current research is also focused towards the finding of predictive biomarkers to further individualize therapy. Biomarkers such as Programmed cell death ligand -1 expression, gene expression profiles, and immune signatures are currently under investigation to forecast and resistance to immune therapy (7) .

The approach of RCC treatment has changed over the past several years with the introduction of targeted therapies and immune therapies, significantly increasing patient outcomes. Ongoing investigation of molecular and immune-based biomarkers, mechanisms of resistance, and new agents holds the promise to further tailor treatment strategies toward more durable responses and improved quality of life for patients with renal cancer.

II. METHODOLOGY

The research articles were analyzed from 2018 to 2023. Data were sourced from high impact medical journals. Finding words like Renal cell carcinoma, Targeted therapy, Immunotherapy, Molecular biomarkers, and Recent RCC treatments.

The criteria included original research articles, systematic reviews, meta-analyses, and reports of clinical trials discussing advances in the diagnosis of RCC, molecular mechanisms involved, therapeutic approaches, and biomarker identification. The aim was finding the research articles involving with diagnostic modalities, molecular genetics, immunotherapy, targeted therapy, and mechanisms of resistance in RCC.

Data extraction involved of summarizing findings related to molecular pathways, diagnostic and prognostic biomarkers, treatment options, and recent development. Additionally other sources including conference proceedings, guidelines from professional society, and expert consensus statements were examined to ensure that the latest advances in the field were comprehensively covered.

III. HISTOPATHOLOGICAL SUBTYPES OF RCC

Renal cell carcinoma comprises various histo pathological subtypes, each with specific molecular profiles, prognostic factors, and treatment responses. The most common subtype includes Clear cell RCC, papillary RCC, chromophobe RCC, and other uncommon variants.

Clear cell RCC is the most common subtype, representing 70-80% of patients with RCC. It shows cells with clear cytoplasm because accumulation of lipid and glycogen, and often presents with VHL gene changes resulting in dysregulated hypoxia-inducible pathways (Linehan et al., 2019). Recent data highlights its high vascular nature and sensitivity to targeted therapy against VEGF pathways (3,4) .

ISSN No:-2456-2165 https://doi.org/10.38124/ijisrt/25jul517

Papillary RCC represent 10-15% of RCC and is further divided into type 1 and type 2 with different molecular signatures. Type 1 is linked to MET gene mutations, while type 2 has fumarate hydratase and SETD2 mutations (8) . Increasing knowledge of the molecular differences has brought about the development of targeted treatments focused on MET inhibitors and other agents.

Chromophobe RCC accounts for approximately 5% of renal cell carcinoma and generally has a good prognosis. Histological it's consisting of large pale cytoplasmic cells with irregular nuclei, and frequent loss of two or more chromosomes. The recent genomic findings indicate abnormalities of mitochondrial and chromosomal stability pathways (9) .

Other Rare Subtypes include collecting duct carcinoma, medullary carcinoma, and unclassified RCC, which constitute less than 5% of the cases. These variants tend to exhibit aggressive clinical behavior and are therefore in need of esoteric diagnostic and therapeutic strategies (10).

A. Molecular Pathogenesis of RCC

The pathogenic and progression of renal cell carcinoma involve complicated mechanism including genetic alterations, dysregulated signaling pathways, and cell to cell involvements in the tumor microenvironment. Understanding these molecular products has been instrumental in development toward targeted therapies and personalized treatment plans.

In the clear cell RCC the most common genetic changes is the non functioning of the VHL tumor suppressor gene on chromosome 3p25.Mutation of VHL results in stabilization of hypoxia-inducible factors, producing tumor growth and angiogenesis (11) . Genetic changes also involve mutations of Polybromo 1, BRCA 1associated protein 1, and SET domain containing 2 , histone lysine methyltransferase, which are changing the appearance of chromatin and epigenetic regulators (2) . Papillary RCC has mutations in the MET proto-oncogene, which contribute irregular cell proliferation (8) .

- *Signaling Pathways Involved*

Hypoxia inducible factors accumulation due to loss of VHL leads to up regulation of vascular endothelial growth factor, producing angiogenesis. This pathway is focused by a number of drugs including bevacizumab and tyrosine kinase inhibitors (3,4) .

The mTOR pathway is often over activated in RCC and controls cell develop, proliferation, and survival. mTOR inhibitors such as everolimus and temsirolimus have been well tolerated in the management of advanced RCC (12).

Mesenchymal epithelial transition mutations produce activation of proliferation and survival pathways, particularly in papillary RCC. MET inhibitors are under research in the clinic (8) .

- *Tumor Microenvironment*

The micro environment of RCC in vasculature, immune cell infiltration, and stromal interactions. The high expression of angiogenic agents as a result of VHL deletion establishes a highly vascularized tumor. Moreover, RCC tumors tend to have mechanisms of immune evasion, such as the expression of immune checkpoint molecules like PD-L1 that are responsible for resistance to immune involvement (McDermott et al., 2018). Recent research have shed light on further molecular pathways, such as epigenetic regulation and immune landscape alterations, that are being considered as new treatment targets (13) .

B. Diagnostic and Prognostic Biomarkers

In the clinical setting, a number of biomarkers used to diagnosis of RCC. Lactate dehydrogenase levels in serum, hemoglobin, and calcium are included in the International Metastatic RCC. Tissue markers such as carbonic anhydrase IX expression have also been investigated, though not in regular practice due to low specificity.

Developing advances have noted molecular biomarkers with potential diagnostic and prognostic valence. Circulating tumor DNA and micro RNAs for example, are being explored for their application in fast detection and monitoring treatment outcome (14).

Gene expressions are accountable for angiogenesis, immune evasion, and epigenetic controls are also being examined for risk stratification and directing targeted treatment. Imaging studies, such as dynamic contrast enhanced MRI and positron emission tomography using new tracers, provide non invasive methods to measure tumor biology, vasculature, and metabolic activity.

Radio mics imaging feature analysis can detect tumor grade, molecular subtype, and response to treatment, as recent researches imply (14). Such imaging biomarkers show promise for individualized treatment of RCC.

C. Current Research on Therapeutic Approaches to RCC

Recent clinical research have established the enhanced therapeutic effect of the combination of immune checkpoint inhibitors and targeted therapy. The COSMIC-313 trial evaluated the combination of cabozantinib, nivolumab, and ipilimumab with assuring results in terms of progression free survival among advanced RCC patients versus recent treatments (4).

New treatments that act on new targets are being explored. For instance, HIF-2α inhibitors PT2385 and PT2977 (MK-6482) are assuring in initial stage trials to suppress hypoxia inducible factors that develop tumor growth in RCC (4) .

Recent research is directed towards the identification of biomarkers that can use detect response to immunotherapy and targeted agents. For example, tumor mutational burden and gene expressions are under investigation to tailor therapy in an attempt to enhance the outcomes (15) .

ISSN No:-2456-2165 https://doi.org/10.38124/ijisrt/25jul517

Trials of the application of ICIs in the adjuvant post nephrectomy setting, including PROSPER with durvalumab, are being conducted to decrease rates of recurrence in high risk localized RCC, with early evidence pointing to benefit (15) .

D. Recent Advances and Novel Therapies in RCC

The current advances in introducing new targeted therapies and immune therapies. For instance, HIF-2α inhibitors such as PT2385 and PT2977 (MK-6482) are promising in early phase trials by addressing hypoxia inducible factors, a major impetus in ccRCC. The COSMIC-313 trial tested the triplet combination of cabozantinib, nivolumab, and ipilimumab, showing better progression-improve survival in advanced RCC (4) . Further, Lenvatinib in combination with pembrolizumab has been shown to be benefit in second line therapies (5) .

Genomic profiling advancements enable individualized therapeutic plans. Recent research is focused at detecting the response to therapy using molecular signatures and genetic mutations to maximize individual patient treatment response. For instance, gene expression profiling helps in determining those patients who are more likely to respond to immunotherapy rather than targeted therapeutic agents (15).

The discovery of predictive biomarkers is an area of active research. Biomarkers such as PD-L1 expression, tumor mutational burden, and gene signatures are being researched to be used to direct therapy choice. A current report suggested that raised PD-L1 expression is associated with improved response to immune checkpoint inhibitors, but its application is still being explored (15) .

IV. CHALLENGES AND FUTURE DIRECTIONS IN RCC

One of the significant challenges in the treatment of RCC is the onset of resistance against existing therapies, especially immune therapies and tyrosine kinase inhibitors. Tumors tend to develop resistance by evolving mechanisms such as high expression of second order signaling pathways, immune escape, and genetic mutations like mutations in VHL, PBRM1 or BAP1 genes. These mechanisms are understood the design methods to overcome resistance, such as combination therapy or sequential treatment methods (3) .

Early detection continues to be elusive because initial stages of RCC are asymptomatic. Enhancing screening technologies, including liquid biopsies that identify circulating tumor DNA or new imaging modalities could responsible earlier treatment and enhanced survival outcomes. Biomarkers for early detection are the recent focus (16) .

Genomic advances have made it possible for personalized therapy, where treatments are accepted according to the genetic profile of tumors. Future importance involves the incorporation of intensive genomic information, transcriptomics, and proteomics into clinical practice to refine the selection of therapy, track response, and anticipate resistance. Establishing molecular systems for RCC should better stratify patients (15) .

Research is still searching new molecular targets outside VEGF and immune checkpoint targets. New targets in the pipeline are HIF-2α, metabolic targets, epigenetic regulators, and tumor microenvironment targets. These present the opportunity to develop next generation therapies with the potential for overcoming resistance (4) .

V. RESULTS

16 papers were read and analyzed for this study. The article findings shows that developed targeted therapy and immunotherapy have greatly increased prognosis for patients with RCC. Radiological imaging continues to be an important diagnostic and monitoring device, as it effectively monitoring the tumor size, metastasis, and response. Molecular profiling analyses have the valuable of biomarkers related to prognosis and drug response, allowing for more personalized treatment options. These improvements, resistance to treatment and delayed diagnosis remain ongoing challenges, which emphasize continued research as well as early detection.

Recent clinical researches have assure that combination of therapies like immune checkpoint blockade with tyrosine kinase inhibitors provide good progression free survival than single therapy, and new agents targeting hypoxia inducible factors are in early investigation , finding for new therapeutic options. Although these advances, resistance development and late presentation continue to assume challenges, and there are continuing efforts to better molecular classification, discover predictive biomarkers, and design next generation therapies to overcome the resistance mechanisms and personalize RCC management.

VI. CONCLUSION

In summarized this review articles underlines the great advancement achieved in the knowledge of molecular and clinical aspects of RCC The understanding of the molecular and clinical features of renal cell carcinoma over the last 5 years have considerably increased diagnostic accuracy, prognosis evaluation, and treatment approach. Development in imaging studies, targeted therapies, and immune therapies have used improve patient management and outcomes.

Molecular profiling has revealed genetic and immunological patho physiology of RCC, allowing for the method of personalized therapies and new biomarkers to enable early detection and monitoring treatment outcomes. To move forward such as therapeutic resistance, tumor diverseness, and delayed diagnosis still occur, underlining the necessity for continuous research in biological mechanisms, early detection, and new therapies. Multidisciplinary approaches include molecular, imaging, and clinical information continues to be necessary for further treatment effects and improve patient survival rates.

ISSN No:-2456-2165 https://doi.org/10.38124/ijisrt/25jul517

RECOMMENDATIONS

To develop RCC management in the future, research should aim to discover and validate innovative molecular biomarkers that facilitate early detection, prognosis, and prediction of response to management. Developing therapeutic approaches according to genetic and immunological profiles is important to improve effect and minimize side effects. Clinical researches investigating and developing combination therapies that include immune checkpoint inhibitors, targeted therapies, and new therapies like HIF 2α inhibitors are important to eliminate resistance and prolong treatment duration.

Additionally, developing imaging modalities such as radiomics and liquid biopsy methods can improve non invasive tumor profiling and real time monitoring. Exploration of resistance mechanisms in greater depth will inform the development of strategies to prolong treatment durations and reduce disease progression in RCC. The screening pathways that include molecular and imaging biomarkers will felicitate earlier diagnosis and develop overall survival. Finally, multidisciplinary collaboration between urologists, oncologists, radiologists, and molecular biologists is important for successful of research into clinical practice and increase optimization of patient outcomes.

Conflict of Interest: Nil

REFERENCES

[1]. Capitanio, U., Montorsi, F. (2021). Renal cell carcinoma: Epidemiology, clinical presentation, diagnosis, and management. European Urology, 79(4), 501-515. https://doi.org/10.1016/j.eururo.2020.11.023
[2]. Linehan, W. M., et al. (2019). Molecular Classification of Renal Cell Carcinoma. Nature Reviews Urology, 16(4), 248-264.
[3]. Motzer, R. J., et al. (2023). Mechanisms of Resistance to Targeted Therapies in Renal Cell Carcinoma: Implications for New Treatment Strategies. Nature Reviews Urology, 20(2), 86-98. https://doi.org/10.1038/s41585-022-00612-1
[4]. Choueiri, T. K., et al. (2023). Emerging Therapeutic Targets and Future Directions in RCC. The Lancet Oncology , 24(4), 400-412. https://doi.org/10.1016/S1470-2045(23)00043-9
[5]. Rini, B. I., et al. (2022). Long-term Outcomes of Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal Cell Carcinoma: CheckMate 214. Journal of Clinical Oncology, 40(16), 1796-1806.
[6]. McDermott, D. F., et al. (2020). Biomarkers in Immunotherapy for Renal Cell Carcinoma: Current Perspectives and Future Directions. Nature Reviews Urology, 17(4), 227-238.
[7]. Gupta, M., et al. (2022). Emerging Biomarkers and Therapeutic Targets in Renal Cell Carcinoma. Cancer Treatment Reviews, 103, 102278.
[8]. Albiges, L., et al. (2019). Molecular Subtypes of Clear Cell Renal Cell Carcinoma: Implications for Precision Medicine. Nature Reviews Urology, 16(9), 521-537.
[9]. Ding, H., et al. (2020). Genomic Characterization of Chromophobe Renal Cell Carcinoma. Nature Communications, 11, 598.
[10]. Srigley, J. R., et al. (2018). International Society of Urological Pathology (ISUP) Vancouver Classification of Renal Neoplasia. American Journal of Surgical Pathology, 42(9), 1233-1238.
[11]. Gorini, G., et al. (2018). Genetic and Epigenetic Alterations in Kidney Cancer. Cancer Biology & Therapy, 19(4), 359-370.
[12]. Hudes, G., et al. (2014). Temsirolimus, Interferon alfa, or Both for Advanced Renal-Cell Carcinoma. New England Journal of Medicine, 356(22), 2271-2281.
[13]. Sato, T., et al. (2021). Molecular mechanisms and therapeutic targets in renal cell carcinoma: recent advances. Nature Reviews Urology, 18, 153-171.
[14]. Liu, Z., et al. (2023). Radiomics in Renal Cell Carcinoma: Applications, Challenges, and Future Directions. European Radiology, 33(4), 2492-2504.
[15]. McKay, R. R., et al. (2022). Integrating Genomics into Personalized Treatment of RCC: Progress and Challenges. Nature Reviews Urology, 19(3), 157-172. https://doi.org/10.1038/s41585-022-00588-7
[16]. Johnson, A., et al. (2022). Early Detection of Renal Cell Carcinoma Using Liquid Biopsies: Current Status and Future Perspectives. Cancer Research, 82(12), 2347-2355. https://doi.org/10.1158/0008-5472.CAN-22-0458